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Pan-active imidazolopiperazine antimalarials target
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A promising new compound class for treating human malaria is the imidazolopiperazines
(IZP) class. IZP compounds KAF156 (Ganaplacide) and GNF179 are effective against Plas-
modium symptomatic asexual blood-stage infections, and are able to prevent transmission
and block infection in animal models. But despite the identification of resistance mechanisms
in P. falciparum, the mode of action of IZPs remains unknown. To investigate, we here
combine in vitro evolution and genome analysis in Saccharomyces cerevisiae with molecular,
metabolomic, and chemogenomic methods in P. falciparum. Our findings reveal that IZP-
resistant S. cerevisiae clones carry mutations in genes involved in Endoplasmic Reticulum
(ER)-based lipid homeostasis and autophagy. In Plasmodium, IZPs inhibit protein trafficking,
block the establishment of new permeation pathways, and cause ER expansion. Our data
highlight a mechanism for blocking parasite development that is distinct from those of
standard compounds used to treat malaria, and demonstrate the potential of IZPs for
studying ER-dependent protein processing.
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Malaria remains the most common human parasitic dis-ease, sickening an estimated 219 million peopleannually and causing an estimated 435,000 deaths
worldwide1. Although a reduction in the malaria burden has been
achieved through the combined use of public health infra-
structure, vector control, and increased access to medical
treatment2,3, these efforts are hindered by a variety of factors,
such as the lack of an effective vaccine, increased mosquito
resistance to pesticides, and the continuing emergence of drug-
resistant parasite strains4–6. Currently, resistance has been
reported against nearly all classes of antimalarial compounds
deployed in the field such the quinoline-type drugs (i.e. chlor-
oquine, mefloquine, amodiaquine etc), antifolates (sulfadoxine/
pyrimethamine), and naphthoquinones (atovaquone)7–9. And
perhaps most alarming of all, resistance against the endoperoxide
artemisinin—a central component of malaria control programs
worldwide—is also emerging10. Given that an estimated 3.2 bil-
lion people live in endemic regions and are at risk for malaria3,
new classes of antimalarial compounds will be required to combat
and ultimately eradicate this disease.
One of the most promising classes of compounds are the
imidazolopiperazines (IZPs), such as KAF15611 and its closely
related analog GNF17912, which differs from KAF156 by a single
halogen substitution (F to Cl). The chemotype that led to KAF156
was first identified in a phenotypic screen designed to discover
compounds with activity against parasite asexual blood stages13.
The compound series attracted more attention when it was noted
that multiple analogs were present in the library, which all
showed activity in a liver stage model that predicts causal anti-
malarial prophylaxis12. Subsequent rounds of medicinal
chemistry14,15 led to the development of KAF156, an orally
available, simple-to-synthesize compound suitable for testing in
humans11.
KAF156 shows potent activity against asexual blood (IC50 ~ 6 nM),
hepatic (IC50= 4.5 nM) and sexual stages (IC50= 5 nM)11, and is
considered safe with good pharmacokinetic properties in healthy
human volunteers16. Because the compound was able to dramatically
reduce parasite numbers in patients with P. vivax and P. falciparum
patients in a single agent trial17 it has now progressed to phase IIb
clinical trials (NCT03167242) where it is being tested in combination
with lumefantrine. It also has impressive prophylactic activity:
treating mice with a single 10mg/kg oral dose fully protects them
from mosquito-borne malaria infection. Furthermore, IZPs have
gametocytocidal activity and including them in a blood meal or
pretreating with IZPs prevents parasites from being transmissible to
mosquitoes11, both in vitro and in vivo. If licensed, IZPs have the
potential to be as significantly impactful on combating malaria as
current gold standard treatments, such as artemisinin-based combi-
nation therapies. With its high potency and capacity to prevent and
treat malaria as well as inhibit transmission, KAF156 could serve as
an important tool in the mission to eliminate this disease.
Previous studies using in vitro evolution and whole-genome
analysis in P. falciparum parasites showed that resistance to IZPs
is mediated by mutations in three different genes including pfcarl,
the cyclic amine resistance transporter (PF3D7_0321900);11,12
pfact, the Acetyl-CoA transporter (PF3D7_1036800); and pfugt,
the UDP-galactose transporter (PF3D7_1113300)18. GFP-tagging
and localization experiments have shown that these three trans-
membrane transporters are all localized to the endoplasmic
reticulum (ER)/Golgi apparatus in Plasmodium. Multiple
resistance-conferring alleles have been recovered independently
in pfact and pfcarl.
It is unlikely that the nonessential pfact encodes the target,
although in human cells the pfact ortholog, AT-1, appears
essential18 :parasite mutants with stop codons as well as frame-
shifts are readily recovered after KAF156 treatment, although it is
possible that mutations in pfact may confer a growth dis-
advantage to the parasite19. Like the parasite protein, the human
protein is also localized to the ER where it serves to import
Acetyl-CoA for use in lysine acetylation of some newly synthe-
sized protein. Its disruption in human cells results in a
proteasome-independent endoplasmic reticulum-associated
degradation (ERAD)(II) mechanism involving the unfolded
protein response and autophagy of the ER18. In humans,
mutating lysines for some proteins such as BACE results in
proteins that are retained in aggregates in the ER. Many Plas-
modium proteins are acetylated20, often at conserved residues,
although it is not clear that this happens in the ER and which
acetyl transferases are responsible.
Pfugt encodes a member of the Solute Carrier 35 Family.
Members of this family play a role in import of sugars to the ER/
Golgi where most glycoconjugate synthesis occurs21. Disruption
of some orthologs in worms and plants also lead to ER stress22,23.
Disruption mutants in pfugt have not been obtained in high-
throughput approaches in P. falciparum indicating essentiality,
however, the small size of the gene and certain sequence features
could contribute to the intractability of pfugt to mutagenesis
screens19. Although PfCARL appears essential19, mutations in
pfcarl confer resistance to unrelated compounds24,25 and
resistance-conferring mutations in pfcarl are located in trans-
membrane regions and not in an obvious catalytic site. PfCARL,
although conserved in evolution, remains understudied, but its
yeast ortholog, Emp65 (Endoplasmic Reticulum Membrane
Protein 65) protects folding polypeptides from promiscuous
degradation26. Mutations in all three parasite proteins may lead
to slower rates of protein folding, processing, and sorting.
Parasites treated with IZPs have also been subjected to meta-
bolic profiling along with other clinical compounds with known
modes of action. Allman et al.27 measured changes in 113
metabolites after treatment with KAF156. These data did not
show a clear metabolic perturbation, in contrast to inhibitors of
cytochrome bc1, dihydroorotate dehydrogenase, PfATP4, or
dihydrofolate reductase, many of which are also active in both
blood and hepatic stages.
Given the clinical potential of GNF179, determining its
mechanism of action could reveal important new druggable
pathways, suggest synergistic drugs that could be used in com-
bination therapies, and provide clues on possible toxicity. Here
we report on a series of experiments in P. falciparum and S.
cerevisiae to discern the mode of action of this important anti-
malarial compound series.
Results
Identification of potential GNF179 targets in S. cerevisiae. For
target identification, we first used in vitro evolution studies in the
model system Saccharomyces cerevisiae, a strategy that has been
used to discover the target of cladosporin, a tRNA synthetase
inhibitor that acts against both P. falciparum and S. cerevisiae. We
have recently demonstrated that yeast can be successfully used for
drug target identification in both antimalarial and anti-
trypanosomal compounds28–30, so we decided to perform selec-
tions with GNF179. IZPs are moderately active (45 μM) against
an attenuated strain of Saccharomyces that has been genetically
modified by replacing 16 ABC multi-drug transporter genes with
modified Aequorea victoria GFP (eGFP) and that has been dub-
bed the “Green Monster”31. Altogether, 13 different, independent
IZP-resistant yeast lines were created by growing the cells for a
minimum of 20 generations in the presence of increasing
GNF179 concentrations until resistance was observed (with a
minimum 1.5x IC50 increase for GNF179) (Table 1). Clonal lines
were isolated from each resistant culture and retested for
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sensitivity. The observed resistant strains exhibited 1.5–3.1-fold
resistance relative to the drug-naïve Green Monster strain.
We sequenced drug-resistant genomes to an average 47.3x
coverage and compared these to the drug-sensitive parent
(Supplementary Table 1). Excluding mutations in repetitive
elements, we detected 67 total variants including 49 missense,
frameshift or nonsense variants, 2 synonymous variants, 2
inframe deletions and 14 intergenics (Supplementary Data 1).
The high proportion of coding to silent mutations suggests that
most changes have a beneficial effect. Multiple independent alleles
were found in six different genes arising in independent selections
(sec66(2 variants), elo2(5), lcb4(3), YMR102C(4), atg15(4) and
sur2(3)), with the most resistant lines harboring multiple
mutations (e.g. GNF179-R19g2 with YMR102C, atg15 and sur2)
although not generally in catalytic domains (Fig. 1a). With ~5800
genes in the genome, the probability of finding more than one
allele by chance in the same gene after in vitro evolution is very
low (p= 4.4e-7) and highlights the reproducibility of the
selections. In addition, the set of 38 variants included singletons
in the closely related genes sur1, elo3, and atg22. This mutational
pattern is specific to IZPs and has not been observed for in vitro
evolution with other antimalarial compounds whose targets have
been identified using the Green Monster system30,32.
With the exception of YMR102C, whose function is not
known, these genes are all directly or indirectly associated with
trafficking and processes in the ER (Fig. 1b). SEC66 encodes a
non-essential subunit of the SEC63 complex that forms a channel
competent for SRP-dependent and post-translational SRP-
independent protein targeting and import into the ER. SEC66
disruption is well known to slow the process of protein
trafficking, such that the accumulation of differently-sized
trafficking intermediates becomes evident by gel electrophoresis
and immunodetection33. Similarly, ELO2 and ELO3, which
encode fatty acid elongases that contribute to sphingolipid
biosynthesis in the ER, were identified in a protein trafficking
screen: Alleles in both ELO2 and ELO3, named VBM1 and
VBM234, were identified as suppressors of a v-SNARE mutant in
which yeast cells accumulate post-Golgi secretory vesicles, and are
defective in invertase secretion35. ATG15 and ATG22 play a role
in autophagy, which is induced in proteasome-independent ER
expansion that results from aggregates of misfolded proteins.
SUR1 (the catalytic subunit of mannosylinositol phosphorylcer-
amide (MIPC) synthase that is required for biosynthesis of
mature sphingolipids), SUR2 (sphingosine hydroxylase involved
in sphingolipid metabolism), and LCB4 (sphingoid long-chain
base kinase) are all part of the sphingolipid metabolism pathway,
which is carried out in the ER. Sphingolipids and long-chain fatty
acids play a role in regulating autophagy. The identification of
resistance-conferring genes in S. cerevisiae whose products are
localized to the ER or Golgi is similar to observations in P.
falciparum, where parasite lines that have been evolved to be
profoundly resistant to GNF179 also develop mutations in
transporters located in the ER/Golgi complex (Supplementary
Table 4).
As these resistant strains often harbored multiple mutations, we
used CRISPR-Cas9 based genome editing to introduce these
mutations in a drug-naïve Green Monster genetic background. For
sec66 (M1I, IC50= 70.1 ± 11.7 µM, S107*, IC50= 74.83 ± 9.4 µM),
elo2 (G183C IC50= 88.15 ± 8.7 µM) and elo3 (Y307*, IC50=
76.57 ± 10.0 µM) vs wild-type (WT) Green Monster IC50= 47.3 ±
3.8 µM (Table 2), the CRISPR-edited lines exhibited similar, 1.5 to
1.9-fold levels of resistance to the drug-pressure derived lines,
indicating that these three genes were responsible for the
resistance observed in those yeast strains.
Some of the mutations (e.g. elo2, sur2, atg15, and sec66) were
early stop codons and therefore resulted in truncated proteins. To
provide a further layer of confirmation for the in vitro resistance
experiments, the homozygous deletion strains (which are not
attenuated like the Green Monster strain)36,37 for sec66, sur2,
atg15, and elo2 were tested against GNF179, revealing each to be
1.3 to 2.1-fold more resistant to IZPs (IC50= 121.26 ± 2.9 µM
(WT) vs 188.69 ± 11.4 µM (sec66Δ), 254.88 ± 55.1 µM (elo2Δ),
Table 1 Mutations identified in more than one GNF179-resistant S. cerevisiae line, from a pool of 13 evolved strains.
Standard and systematic gene name Strain/clone name Amino acid change GNF179
IC50 (µM)
GNF179-fold
resistance (FR)
N/A ABC16-Monster-
Parent
N/A 45.39 ± 5.7 N/A
ELO2 (YCR034W) Fatty acid elongase, involved in
sphingolipid biosynthesis
GNF179-R9-2 G183C 81.18+ 6.3 1.8
GNF179-R10-2 G183C 90.31 ± 14.8 2.0
GNF179-R18g1 L193W 137.66 ± 5.1 3.0
GNF179-R8h2 L169R 138.05a 3.0
GNF179-R9f2 A186D 94.7 ± 41.3 2.1
SUR2 (YDR297W) Sphingosine C4-hydroxylase GNF179-R18g1 S94* 137.66 ± 5.1 3.0
GNF179-R19g2 D257Y 109.35 ± 23.1 2.4
GNF179-R9f2 I108K 94.7 ± 41.3 2.1
ATG15(YCR068W) Phospholipase GNF179-R18g1 W200* 137.66 ± 5.1 3.0
GNF179-R19g2 C271Y 109.35 ± 23.1 2.4
GNF179-R9f2 W380* 94.7 ± 41.3 2.1
GNF179-R8h2 K303fs 138.05a 3.0
LCB4 (YOR171C) Sphingoid long-chain base kinase GNF179-R9f2 Y421N/A423S 94.7 ± 41.3 2.1
GNF179-R8h2 T336K 138.05a 3.0
YMR102C Protein of unknown function GNF179-R19g2 S448W 109.35 ± 23.1 2.4
GNF179-R9f2 F381V 94.7 ± 41.3 2.1
GNF179-R18g1 L271fs 137.66 ± 5.1 3.0
GNF179-R8h2 Q98fs 138.05a 3.0
SEC66 (YBR171W) GNF179-R1-2 S107* 80.12 ± 14.6 1.8
Non-essential subunit of Sec63 complex GNF179-R12-2 M1I 67.22 ± 10.4 1.5
Eighteen hours IC50s against GNF179 (mean ± standard error with n≥ 2) and fold resistances (calculated relative to the parental ABC16-Monster-Parent strain) are indicated. The complete set of coding
changes for the 13 resistant lines are given in Supplementary Data 1.
aReplicate not available.
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and 217.9 ± 12.5 µM (sur2Δ) respectively). We found that the
homozygous deletion strain for yer140w (which encodes the
PfCARL homolog EMP6538) showed low-level resistance to IZPs
(152.2 ± 10.5 µM), and a homozygous deletion of sec72, another
nonessential subunit of the complex for importing proteins
into the ER, also conveyed a similar level of resistance (177.37 ±
5.1 µM) (Table 3). These data suggest that modifications to either
the protein export complex or lipid synthesis pathways or both
can result in IZP resistance in yeast. Although the observed
mutations may help overcome GNF179 treatment, it seems
unlikely that these genes encode targets. Many genes are not
essential and we observe stop codons. In addition, levels of
resistance for isolated alleles are mild.
pfcarl mutant lines show altered sphingolipid profiles. To
explore sphingolipid inhibition as a potential mechanism of
action, we used a HPLC (high pressure liquid chromatography)
linked to triple quadrupole mass spectrometry (LC-MS/MS) to
measure 19 classes of sphingolipids in P. falciparum Dd2 para-
sites exposed to 5x IC50 (30 nM) GNF179 for 4 h. Of note, prior
work has demonstrated mammalian-like sphingolipid biosyn-
thetic activities in Plasmodium parasites39. Results with Dd2 WT
parasites were compared to the pfcarl triple mutant (KAD452-R3;
M81I, L830V and S1076I) that was earlier generated through
in vitro evolution and is profoundly resistant to IZPs (370-fold
and 340-fold resistant to KAF156 and GNF179, respectively)25.
LC-MS/MS analysis of saponin-lysed parasite extracts identified
dihydroceramides (DH), ceramides (C), sphingosines (So),
sphinganines (Sa), and sphingomyelins (SM), with varying fatty
acid chains and degree of saturation (Supplementary Fig. 1a-d).
Normalized lipidomic comparison of untreated wild-type and
mutant parasites indicated that the baseline sphingolipid
concentration was notably lower in the pfcarl mutant (denoted
KAD). Ceramide levels (Supplementary Fig. 1b) in untreated
wild-type parasites were found to be consistently higher than in
the mutant, with statistical significance being observed in three
out of the six identified species (C16, C20, C24). Notably,
PPI enrichment p-value: 1.38 × 10–14
ELO family, conserved site ELO family, conserved site
TRAM/LAG1/CLN8 homology domain
Diacylglycerol kinase, catalytic domain
VASt domain VASt domain
VASt domain VASt domain
WD40 repeat region
Known interactions
From curated databases
Experimentally datermined
Predicted interactions
Gene neighborhood
Other criteria
Co-expression
Protein homology
Text mining
a b
Fig. 1 GNF179-resistant yeast strains harbor mutations in endoplasmic reticulum(ER)-based lipid homeostasis and autophagy genes. a Protein maps
showing relevant mutations and PROSITE predicted protein domains, if applicable. Maps were generated using Illustrator of Biological Sequences (IBS)
software package86. Missense mutations are shown in yellow ovals, nonsense mutations in red pentagons, and frameshift mutations as purple arrows.
b Protein–protein interaction (PPI) network was generated using the STRING database87. Each node represents a S. cerevisiae protein and connecting lines
delineate interactions. The PPI enrichment p-value (p= 1.38 × 10−14) indicates that the proteins show significantly more interactions among themselves
than would be expected from a random subset of genes from the yeast genome.
Table 2 IC50s (mean and S.E.M) for GNF179 in the indicated yeast CRISPR-Cas9 edited strains.
Strain name Systematic
gene ID
Standard
gene name
Mutation Gene description GNF179
IC50 (µM)
GNF179-fold
resistance (FR)
ABC16-Monster N/A N/A N/A N/A 47.30 ± 3.8 N/A
EAW361 YBR171W SEC66 M1I Non-essential subunit of Sec63
complex, involved in protein targeting
and import into the ER
70.10 ± 11.7 1.5
EAW277 YBR171W SEC66 S107* Non-essential subunit of Sec63
complex, involved in protein targeting
and import into the ER
74.83 ± 9.4 1.6
EAW289 YCR034W ELO2 G183C Fatty acid elongase, involved in
sphingolipid biosynthesis;
88.15 ± 8.7 1.9
EAW327 YLR372W ELO3 Y307* Fatty acid elongase, involved in
sphingolipid biosynthesis;
76.57 ± 10.0 1.6
Strain name, systematic name, 18 h IC50s against GNF179 (mean ± standard error with n≥ 3) and relative change compared to unedited ABC16-Monster strain are indicated.
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sphingomyelins (SM C18, SM C18:1) were significantly lower
compared to Dd2 (Supplementary Fig. 1d). This could also be
observed with sphinganine (Sa, also known as sphingosine) that
showed 2-fold lower levels in the pfcarl mutant compared to its
parental Dd2 line (Supplementary Fig. 1c). Lower levels were also
observed for several dihydroceramides (Supplementary Fig. 1a),
which can be derived from Sa via the addition of fatty acids of
varying chain lengths and (de)saturation states (Supplementary
Fig. 1e); As an example, C18:1 dihydroceramide was undetectable
in mutant parasites. KAD and Dd2 parasites treated with
GNF179, however, showed SL levels that were largely unchanged
compared to untreated controls, suggesting that GNF179 does not
directly inhibit SL synthesis. Further studies will be informative in
assessing whether other lipid species, such as phospholipids, also
show differences in their abundance in the KAD mutant line. The
SL differences observed in the pfcarl mutant line are supportive of
shared mechanisms of resistance to GNF179 between Plasmo-
dium and yeast.
Localization of GNF179 within the parasite. To gain further
insight into the compound’s function we next examined sub-
cellular localization using a fluorescently-conjugated form of
GNF179 in P. falciparum, as recently performed for prima-
quine40. We first generated both NBD- or Coumarin-1-
conjugated forms of GNF179 (Fig. 2a), leveraging an existing
reaction series41. These modified compounds retained activity
against P. falciparum blood stages, though the potency was
noticeably reduced for the Coumarin-1 conjugated form of
GNF179 (19 nM for NBD and 1.2 µM Coumarin-1 vs 5 nM for
non-modified GNF179). However, the GNF179-resistant strain
(KAD452-R3) was also resistant to the modified forms of
GNF179 (Fig. 2b), indicating a similar mechanism of action for
the labeled and unlabeled compounds. We first examined the
localization of GNF179 in ring-stage parasites, as previous reports
indicated that GNF179 is most active against early blood stages25.
GNF179 colocalized with ER tracker Red, a live-cell dye that
recognizes the ER42 (Fig. 2c). This, combined with the S. cerevi-
siae data and the localization of the three previously identified
resistance genes (pfact, pfugt, and pfcarl) to the ER/Golgi, suggest
that IZPs affect a process within this compartment.
GNF179 inhibits protein export in P. falciparum. To further
explore the hypothesis that GNF179 blocks the production or
sorting of mature proteins, we next tested for synergy with known
protein-export inhibitors. Brefeldin A inhibits Sec7-type GTP-
exchange factors (GEFs) that catalyze the activation of a small
GTPase called Arf1, responsible for ER to Golgi transport, as well
as Golgi to ER retrograde transport, through the inhibition of
COPI coating of secretory vesicles43, and is commonly used to
inhibit protein secretion. We observed that treating parasites with
sublethal concentrations of brefeldin A (1 µM) rendered parasites
5-fold more sensitive to GNF179 (IC50 of 0.8 ± 0.22 nM, vs 4.31 ±
0.88 nM without brefeldin A co-treatment) (Table 4), while sen-
sitivity to the control drug artemisinin was unchanged. This
suggests that parasites exposed to GNF179 are highly sensitive to
alterations in protein export.
A similar effect was observed for two other compounds:
golgicidin, another inhibitor of protein export that works through
inhibition of Golgi function44, and KDU691, an inhibitor of
phosphatidylinositol 4-kinase type III beta (PI4KIIIβ)45. Simulta-
neous treatment with 5 µM golgicidin (IC50 11 µM) as well as
with KDU691 (IC50 100 nM) also rendered parasites 2 to 3-fold
more sensitive to GNF179 (Table 4). Interestingly, PI4K—the
target of KDU691—is responsible for catalyzing the phosphor-
ylation of phosphatidylinositol to generate phosphatidylinositol
4-phosphate (PI4P), which is found to be localized in the Golgi
apparatus and plasma membrane of the parasite46. Essential for
the functional and structural maintenance of the Golgi complex,
dysregulation of PI4K—and subsequently PI4P—results in
fragmentation of the complex as well as perturbation of transport
from the Golgi to the plasma membrane47.
Importantly, this observation was specific to GNF179, rather
than merely a sign of generalized parasite growth impairment, as
artemisinin, atovaquone and chloroquine all showed no synergy
with any of these three compounds. This synergistic effect was
exclusive to inhibitors of protein secretion from the ER and Golgi,
as simultaneous treatment with thapsigargin, which inhibits
PfATP6 and causes depletion of ER calcium levels leading to
downstream inhibition of ER chaperones48, caused no change in
GNF179 potency.
In addition, we tested for synergy between GNF179 and
inhibitors of the P. falciparum proteasome (Table 4), to determine
whether the identified increase in ubiquitinated proteins was
directly involved with the efficacy of GNF179 or rather was a
downstream consequence. We did not observe any synergy
between GNF179 and carmaphycin B, a natural product-
derived proteasome inhibitor32. This is in contrast to artemisinin,
which increases the potency of carmaphycin B. This indicated to
us that the increase in protein ubiquitination was a secondary
effect of GNF179 inhibiting protein trafficking, rather than a
direct cause.
Table 3 IC50s (mean and S.E.M) for GNF179 in the indicated yeast haploid deletion strains.
Strain name Systematic name Mutation Gene description GNF179
IC50 (µM)
GNF179-fold
resistance (FR)
BY4742 N/A N/A N/A 121.26 ± 2.9 N/A
sec66Δ YBR171W Haploid deletion of
sec66
Non-essential subunit of Sec63 complex, involved
in protein targeting and import into the ER
188.69 ± 11.4 1.6
sec72Δ YLR292C Haploid deletion of
sec72
Non-essential subunit of Sec63 complex, involved
in protein targeting and import into the ER
177.37 ± 5.1 1.5
elo2Δ YCR034W Haploid deletion
of elo2
Fatty acid elongase, involved in sphingolipid
biosynthesis;
254.88 ± 55.1 2.1
sur2Δ YDR297W Haploid deletion
of sur2
Sphinganine C4-hydroxylase; catalyses the
conversion of sphinganine to phytosphingosine
217.9 ± 12.5 1.8
emp65Δ YER140W Haploid deletion
of emp65
Integral membrane protein of the ER 152.2 ± 10.5 1.3
atg15Δ YCR068W Haploid deletion
of atg15
Phospholipase 137.54 ± 12.9 1.1
Strain name, systematic name, 18 h IC50 against GNF179 (mean ± standard error with n≥ 2) and relative change compared to wild-type are indicated. Strains obtained from yeast deletion collection36.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15440-4 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:1780 | https://doi.org/10.1038/s41467-020-15440-4 | www.nature.com/naturecommunications 5
To more closely examine whether protein secretion was being
blocked, we sequentially looked at protein processing in P.
falciparum. In free-living organisms, proteins are trafficked to
membranes or to the extracellular environment. In intracellular
malaria parasites, however, proteins can be further exported into
the infected red blood cell (RBC) or hepatocyte via the PTEX
complex, a parasite-specific secretory complex located in the
parasitophorous vacuole (PV) membrane49. To examine these
two processes, we used two different transiently-expressed
reporters. The first reporter (Fig. 3a) is based on a PfEMP3-
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Fig. 2 GNF179 localizes to the ER of early stage parasites. a Chemical structure of canonical and NBD conjugated GNF179 and Coumarin-1 conjugated
GNF179. b Dose response curves for GNF179 and Coumarin1 (left) or NBD (right) conjugated GNF179 in wild-type and KAF156-resistant clone (KAD452-
R3, containing three mutations in pfcarl (M81I, L830V and S1076I). c Colocalization of Coumarin-1 conjugated GNF179 with ER-tracker red. d Colocalization
of NBD conjugated GNF179 with ER-tracker red. Parasites are in mid-ring (6-hours post-infection) stage and were treated for 30min with 2 µM GNF179-
Coumarin1 and 100 nM GNF179-NBD. The blue signal represents the DAPI-stained parasite nucleus. Scale bars: 2 µm. Source data for b is provided as a
Source Data file.
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Table 4 Seventy-two-hour SYBR-green IC50s for the indicated compound combinations including GNF179.
Plasmodium falciparum drug treatment GNF179 IC50 (nM) Fold change in IC50 Artemisinin IC50 (nM) Chloroquine IC50 (nM)
Dd2 4.31 ± 0.88 – 19.4 ± 1.2 117 ± 14
Dd2+ 1 µM Brefeldin A 0.80 ± 0.22 0.19 21.1 ± 2.7 108.1 ± 17
Dd2+ 5 uM Golgicidin 1.55 ± 0.3 0.36 20.4 ± 1.9 108 ± 18
Dd2+ 250 nM KDU691 1.8 ± 0.35 0.42 18.0 ± 2.4 90.3 ± 6
Dd2+ 1 mM Thapsigargin 4.42 ± 1.4 1.3 18.4 ± 0.8 139 ± 9.8
Dd2+ 1 nM Carmaphycin B 2.6 ± 0.1 0.75 3.5 ± 1.2 90 ± 5.8
Dd2+ 100 nM Cycloheximide 2.6 ± 0.63 0.75 17.5 ± 1.52 101 ± 13.1
Parasites were synchronized to ring stage before IC50s were measured using the SYBR green method. IC50s presented as Mean ± Standard error with ≥2 biological replicates of two technical
replicates each.
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Fig. 3 Secretion reporter constructs demonstrate that GNF179 inhibits protein export of Plasmodium falciparum. a Protein expression levels of PfEMP3-
GFP reporter. This fusion includes the signal peptide and PEXEL motif of PfEMP3. By immunoblot, three protein products are seen with anti-GFP antibodies.
The three indicated bands, in response to probing with GFP, as follows: 1. Full length protein (black arrow), 2. PEXEL cleaved protein (blue arrow), 3. GFP
degradation product (magenta arrow). HSP70 is used as a loading control. b SERA5ss-GFP fusion reporter treated with GNF179. By immunoblot with anti-
GFP antibodies we see two protein products for this construct: 1. Signal peptide cleaved (blue arrow) and 2. GFP degradation product (magenta arrow).
HSP70 serves as a loading control. c 35S incorporation of newly synthesized amino acids at different concentrations of KAF156, chloroquine (negative
control for inhibition) and cycloheximide (positive control for inhibition). Counts were normalized to data obtained from no-drug controls (NDC) and
presented as mean ± SD (n= 2 independent experiments). Source data for c is provided as a Source Data file.
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GFP fusion protein and includes the first 82 amino acids of
PfEMP3 (PF3D7_0201900) fused to GFP. pfemp3 encodes P.
falciparum Erythrocyte Membrane 3, a protein that is exported to
the surface of the infected RBC and that is needed to form knobs
that permit cellular adhesion to vascular endothelial cell surface
receptors. These 82 amino acids of PfEMP3 include both the
signal peptide and PEXEL motif, a five-amino acid sequence
(RxLxE/Q/D) present in most Plasmodium proteins exported to
the RBC cytosol. This sequence is cleaved by Plasmepsin V, a type
I integral membrane-bound protease with the active domain
located on the luminal side of the endoplasmic reticulum (ER)50.
Based on where the export pathway is blocked, three different
potential protein products may be observed: the full-length fusion
protein, the PEXEL-domain cleaved protein, and the mature GFP
degradation product after it has been exported to the RBC. As a
control, we used WEHI-842, a peptide mimetic Plasmepsin V
inhibitor (EC50= 400 nM)50. Additionally, we also exposed the
reporter lines to brefeldin A, cycloheximide, and an inhibitor of
Signal Peptide Peptidase (SPP) ZLL251. Treatment with WEHI-
842 showed a marked accumulation of the full length,
unprocessed protein relative to the untreated control, as expected,
given the role of Plasmepsin V in cleavage of PEXEL signal
sequences. Interestingly, we also observed the full-length protein
after ZLL2 treatment, suggesting that SPP is also required for the
clearance of Plasmepsin V cleaved signal peptides as well as
signal-peptidase-cleaved signal peptides. Parasites treated with
high doses of GNF179, on the other hand, showed a marked
dose-dependent decrease in levels of all forms of the secreted
reporter construct (Fig. 3a). Strikingly, the western blot profile of
brefeldin A- and cycloheximide-treated parasites were also
different from that of GNF179 treatment. Brefeldin A treatment
resulted in an accumulation of the PEXEL-domain cleaved
protein and a decrease in the GFP-only species, indicating that
while there is no obstruction in PEXEL cleavage, there appears to
be a block in actual export to the host cell. On the other hand,
treatment with cycloheximide resulted in a decrease in signal of
unprocessed and PEXEL-cleaved species indicating an arrest in
the synthesis of new reporter proteins—hence the only signal that
remains is that of the GFP degradation products corresponding to
the reporter proteins already exported prior to treatment. In
contrast, levels of HSP70 protein, which does not have a signal
sequence, were unchanged after treatment with GNF179, WEHI-
842, brefeldin A, cycloheximide or ZLL2. This finding suggests
that proteins trafficked through the ER, but not cytoplasmic
proteins, are being degraded or potentially not being synthesized
due to exposure to GNF179.
The second reporter construct was a SERA5ss-GFP fusion,
containing the signal peptide of SERA5 (PF3D7_0207600) fused
to GFP52 (Fig. 3b). SERA5 is an exported serine protease that
plays a role in parasite egress from the infected RBC53. This
fusion protein is co-translationally inserted to the ER and the
signal peptide is removed by signal peptidase, leading to
trafficking of the mature protein to the PV53. SERA5ss-GFP is
therefore used as a marker of protein secretion to the PV, versus
the infected RBC. The parasites were also treated with SPP
inhibitor ZLL2, in addition to brefeldin A and cycloheximide.
Without treatment, we also observed two protein products for
this chimera corresponding to the signal sequence-cleaved species
as well as the GFP only degradation product. Because the
SERA5ss-GFP reporter is co-translationally processed, we are
unable to see the uncleaved species of the protein. After exposure
to GNF179, the reporter showed a dose-dependent reduction in
overall abundance relative to the HSP70 control, as was observed
for PfEMP3 reporter above (Fig. 3b). Also similar to our previous
findings, brefeldin A treatment produced an accumulation of the
signal sequence-cleaved species and a decrease in the GFP only
species indicating an export block, while in the cycloheximide-
treated cells, the strongest signal can be attributed to the GFP
only degradation product. Treatment with ZLL2, in turn, resulted
in a slight decrease in signal from all reporter species possibly due
to the impairment of SPP-mediated clearance of signal peptidase-
cleaved products in the ER membrane.
Based on results with these two reporter systems, we speculated
that there was an impairment of protein secretion that occurs
before signal peptide cleavage, leading to degradation of the
uncleaved products or potentially a block in synthesis. Although
this could be a result of reduced total protein synthesis, we
observed continued incorporation of 35S methionine after
treatment with GNF179, in contrast with cycloheximide (Fig. 3c).
Thus, if protein synthesis was inhibited, it was likely to be
restricted to a subset of proteins. To test whether the loss of
reporter signal via western blot could be due to enhanced
proteolysis through the ubiquitin system we compared the effects
of MG132, a proteasome inhibitor, on cleaved and uncleaved
reporter levels both in the presence and absence of GNF179.
These data showed that proteasome inhibition, in contrast to
GNF179 inhibition, did not affect the levels or processing of
either the PfEMP3 or the SERA5ss reporter and that there was no
observed synergy with GNF179 (Supplementary Fig. 2a). We also
observed that—as with MG132 treatment—there was a slight
increase in ubiquitination levels after GNF179 treatment, in
addition to altered banding patterns suggesting that different
classes of proteins could be ubiquitinated after treatment with the
two compounds.
To evaluate whether or not GNF179 triggers a significant
downstream phosphorylation of eIF2α, we also probed GNF179-
treated trophozoites with an antibody against the phosphorylated
form of eIF2α (anti-eIF2α-p). As controls, parasites were also
treated with dithiothreitol (DTT)—a known inducer of ER stress,
chloroquine—which does not induce ER stress, as well as
brefeldin A. Here, we found that GNF179 treatment induced a
modest increase in eIF2α phosphorylation, similar to levels
observed with brefeldin A, though not as pronounced as what is
observed with DTT treatment (Supplementary Fig. 2b). Our
findings suggest that GNF179 is able to induce a mild ER stress
response in the parasite.
We also tested whether native parasite proteins that are
normally exported to the surrounding infected RBC would be
retained within the parasite after exposure to GNF179. We
therefore examined the intracellular levels of three PEXEL-
containing proteins: PTP2 (PF3D7_0731100), PIESP2
(PF3D7_0501200), and SERA5 (PF3D7_0207600). In all three
cases, after a short, 3-hour exposure with 10 µM GNF179 (same
conditions as above for the reporters for both GNF179 and
WEHI-842), we observed a modest accumulation of all three
proteins suggesting impairment of protein export from the
parasite (Supplementary Fig. 3). A conditional knockdown of
PfSEC62 using the glmS ribozyme system54,55 showed that
parasites were 3-fold more sensitive to GNF179 (0.66 nM for 3D7
wildtype vs 0.24 nM for PfSEC62 kd) (Supplementary Fig. 4).
Finally, we validated the effect of GNF179 on parasite protein
export in live parasites through two parallel strategies, using
brefeldin A as a positive control: visualization of export of
fluorescent reporter proteins, and examination of functional
phenotypes that would result from inhibition of protein secretion.
To begin, we constructed a parasite strain that bears a fusion
between the Knob-Associated Histidine Rich Protein and GFP56
(Fig. 4a). The chimeric gene, which consists of the first 69 amino
acids of KAHRP containing the signal peptide (SP) and PEXEL
motif (Px), was expressed from a pfcrt promoter and was
integrated into the cg6 locus in Dd2-attB parasites using the
attP × attB integrase system57. To better understand in which
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subcellular compartment the export block occurred we co-stained
with antibodies to both the cis-Golgi resident protein, ERD258,
and to the ER (PDI). In the absence of GNF179 the GFP
reporter was trafficked to the PV as well as to the RBC cytosol, as
shown by the GFP staining in and outside the PV surrounding
the parasite (Fig. 4b, Supplementary Fig. 5a). In contrast,
treatment with brefeldin A resulted in accumulation of the GFP
reporter in the parasite ER as evidenced when co-staining with an
anti-PDI antibody (cyan) (Fig. 4c, f) or by using ER tracker (red)
(Supplementary Fig. 5c, f). The white dotted outlines indicate
overlap of green and cyan labels. We also observed some
colocalization between the GFP and ERD2 signal (Fig. 4c, e)
under brefeldin A treatment, though this correlation is lower
than what is seen between GFP and PDI. Interestingly, treatment
with 5x IC50 GNF179 (25 nM) for 16 hours did not show
significant colocalization of the GFP signal with either organelle
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specifically (Fig. 4, Supplementary Fig. 5). While the images
clearly demonstrate inhibition of KAHRP-GFP export, the
Pearson correlation coefficient between the GFP-ERD2 (Fig. 4e),
GFP-PDI (Fig. 4f), and GFP-ER tracker (Supplementary Fig. 5f)
signals indicate that the GFP signal is not significantly over-
lapping with either marker though it appears to be closely
associated with the ER. Additionally, staining of parasites with
ER-tracker after GNF179 treatment showed an expansion of the
ER tracker positive space relative to nuclear staining (Supple-
mentary Fig. 5d). 3D volume quantification of the ratio between
DAPI-positive staining to ER-staining in live, GNF179-treated
parasites showed a statistically-significant expansion of the ER
(Supplementary Fig. 5e). We speculate that the signal is being
sequestered in intermediate compartments that are highly
associated with the ER-Golgi complex. Two candidates in
particular, come to mind: ERGIC, the ER-Golgi Intermediate
Compartment, a known system of membrane clusters where
anterograde and retrograde transport take place59; or the newly
identified TIGER domain, a subcellular compartment that is
intertwined with the ER and is thought to be responsible for
enabling the formation of specific protein interactions in newly
translated membrane proteins60.
To functionally confirm a secretion defect, we next determined
whether parasites treated with GNF179 would be less sensitive to
sorbitol treatment, which kills mature parasites and is used to
synchronize cultures as only ring-stage parasites survive. For
sorbitol to kill later stage parasites, the new permeability
pathways (NPPs) must first be established in the RBC, which
requires the export of a network of transport proteins61 (Fig. 4g).
Here, we observed that 4 h of pretreatment with 25 nM GNF179
led to a loss of sensitivity to sorbitol, as seen via the presence of a
nearly asynchronous culture 24 h post synchronization (Fig. 4h).
This was in contrast to parasites that were GNF179-resistant,
resulting from mutations in either pfcarl (KAD452-R3), or, to a
lesser degree, pfact (Dd2-ACTStop) (Fig. 4h). Those resistant
parasites showed less protection and more sorbitol lysis. As
controls we observed a similar phenotype with brefeldin A but
not with chloroquine. The lack of sorbitol sensitivity in the
presence of GNF179 further highlights the impairment of ER-
mediated protein trafficking due to GNF179 exposure.
Discussion
Once the parasite has successfully invaded the host cell, the
parasite undergoes a rapid induction of protein synthesis62. This
includes the folding and sorting of hundreds of membrane pro-
teins and the secretion of hundreds of proteins into the host cell
via the parasite ER and the PTEX complex in the PVM, leading to
a dramatic rearrangement of host cell processes, all essential for
parasite survival. Proteins needed for these essential processes
may make effective drug targets, as shown by the development of
WEHI-842, an inhibitor of Plasmepsin V63. In addition, KDU691
targets PI4K45, a protein involved in a variety of processes
including vesicular trafficking from the Golgi apparatus. While
the trafficking of proteins into the infected RBC may only occur
during the asexual blood stage, general trafficking and protein
modification is a process that occurs, at least to some degree, at all
stages of parasite development. Therefore, proteins that play a
role in protein processing or sorting pathways would be logical
targets for the type of multistage (hepatic, asexual blood, and
gametocyte stages) activity possessed by IZPs.
The ER serves as the initial entry into the protein trafficking
and secretion pathways, as a site for protein folding, and as the
location of a significant portion of the post-translation mod-
ification of parasite proteins. All of our available data suggest that
IZPs exerts their effect in this organelle, including the localization
of gene products that give resistance (in both S. cerevisiae and P.
falciparum) to KAF156/GNF179 as well as the localization of
NBD and Coumarin-labeled compounds. The ER is responsible
for many functions, including lysine acetylation, protein folding,
glycosylation and sphingolipid biosynthesis (Supplementary
Fig. 6). After proteins have been modified and folded, they are
sorted to other compartments. While KAF156/GNF179 may
block the sorting of proteins to other compartments, our data
seem more compatible with these compounds working at an
earlier stage of protein production, possibly during protein
folding. Western blot analysis shows a substantial reduction in
the total amounts of secreted reporter proteins relative to cyto-
plasmic proteins after GNF179 treatment, suggesting that the
synthesis of both membrane and PTEX-trafficked proteins may
be disrupted. The reduction in protein levels is in contrast to
using the WEHI-842 inhibitor of the ER-based Plasmepsin V
export protease, where a shift from the processed to the unpro-
cessed form of the protein is observed yet protein reporter levels
stay high. Levels of proteins that are not exported to the RBC but
have a simple signal sequence are also reduced (Fig. 3).
While a block in the synthesis of membrane proteins might be
expected to result in an unfolded protein response and synergy
with proteasome inhibitors such as carmaphycin B, there are
different degradation pathways for cytoplasmic proteins versus
proteins that are destined to be secreted. Recent data reveal the
existence of two pathways for dealing with protein aggregates in
the ER: ERAD(I) and ERAD(II)64. While ERAD(I) is driven by
the ubiquitylation-dependent proteasomal degradation of target
proteins, ERAD(II) depends on autophagy and lysosomal traf-
ficking for the disposal of large protein aggregates, and is
observed in human cells when Acetyl-CoA Transporter is dis-
rupted65. It is likely that ERAD(II) is used when secreted
reporters (e.g. KAHRP69-GFP) are overexpressed, as we observed
no great increase in ubiquitinated proteins after GNF179 treat-
ment except when a proteasome inhibitor (MG132) was used in
combination with GNF179 (Fig. S2). An expansion of the ER,
Fig. 4 Confirmation of GNF179’s inhibition of protein export in P. falciparum blood stage parasites. a Vector used for assays shown in b–d. b–d Imaging
of GFP reporter to the plasma membrane under the indicated compound treatments for 16 h. Parasites were fixed and stained with Hoechst 33342 (blue),
α-GFP (green), α-ERD2 (red) and α-PDI (cyan) antibodies. Scale bars: 2 µm unless otherwise indicated. Overlay: DIC images merged with fluorescent
channels. Quantification of colocalization between KAHRP-GFP and ERD2 (e), and between KAHRP-GFP and PDI (f) are indicated by Pearson correlation
coefficient (PCC); Each dot represents an individual parasitized red blood cell. Statistical significance was evaluated using an unpaired, two-tailed t-test
where where * is p < 0.05, ** is p < 0.01, *** is p < 0.001, and **** is p < 0.0001. g Model for establishing new permeation pathways. If proteins are not
exported to the red cell where they can form new permeation pathways, sorbitol will not be imported and cause lysis. h Percentage of rings (mean ± SEM,
at least three independent experiments) from an asynchronous parasite population 24 h after sorbitol synchronization, treated as indicated by GNF179
(5 nM), Chloroquine (CQ, 500 nM) or brefeldin A (BFA, 5 µM). Statistical significance was determined using a paired, two-tailed t-test where * is p < 0.05,
** is p < 0.01, and *** is p < 0.001. Dd2 pfcarl experiments were conducted with the pfcarl evolved triple mutant (KAD452-R3) and edited Dd2-ACTStop
mutant. For sensitive parasites (Dd2), 25 nM of GNF179 was used, while 1 µM was used on resistant parasites. Source data for e, f, and h are provided as a
Source Data file.
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similar to that observed after GNF179 treatment in malaria
parasites (Fig. S5), is observed when yeast cells are treated with
agents that induce the unfolded protein response. ER expansion
induces autophagy as a mechanism to deal with ER-stress and
eliminate the blockage66.
Although GNF179 appears to work in the ER, its exact target
remains unknown. The cancer and antinfectives drug discovery
communities have explored this organelle and its processes as
targets (reviewed in ref. 67); notably, the ER protein-folding fac-
tory examined here also contains targets for antivirals as viruses
need to be packaged within the ER67. In addition, it has been
established that the P. falciparum Signal Peptide Peptidase
PfSPP1 is a drug-able target and its inhibition results in parasite
death across the lifecycle68. Conservation of critical targets across
species seems to be more the rule than the exception although
selectivity of inhibitors may be very different.
Although it is difficult to predict a target based on chemical
structure, KAF156/GNF179 has structural features that suggest it
may inhibit a kinase or other ATP or GTP binding proteins.
Many potential essential targets with ATP or GTP binding
pockets are present in the ER-dependent protein packaging
pathway. Members of the Sec62 translocon complex could be
possible targets. However, Sec62 does not have an obvious cata-
lytic site, a feature that is associated with many targets, although it
is possible that IZPs are allosteric inhibitors. Signal recognition
particle (SRP) is a protein complex critical for the translocation of
proteins into the ER69. Within this complex, both SRP54 and
SRPα harbor GTPase domains, both of which would represent
prime drug-able targets. However, these data would not explain
the increased ER volume that is observed with GNF179-exposed
parasites. Other candidates may include heatshock proteins such
as the GRP94-like protein endoplasmin (PF3D7_1222300). This
essential protein has an ATP-binding domain and selective tar-
geting with small molecule inhibitors is possible70. GRP94
homologs are not found in yeast and bacteria. However, GRP94 is
functionally similar to HSP82. In fact, in our yeast selections we
detect a Ser to Ile substitution at position 17 that lies in proximity
to the ATP-binding pocket. However, the lack of a close ortholog
may explain the 10,000-fold difference in potency in the yeast
model. In addition, binding immunoglobulin protein (BiP), the
Hsp70 homologue within the ER (PF3D7_0917900), requires
ATPase activity to perform the final step of protein translocation
from the SEC61 translocon into the ER71 and could also be a
plausible target. Chemical targeting of BiP is feasible72. The
hypothesis that KAF156/GNF179 targets protein folding in the
ER is supported by the role of EMP65 as a guardian factor that
protects newly synthesized, unfolded polypeptides from degra-
dation (See Supplementary Fig. 6 for model). If pfcarl-emp65 is
mutated, more premature degradation may occur in the presence
of GNF179/KAF156, which may allow the cells to tolerate 10X
more GNF179.
Another potential class of proteins are Rab GTPases. Given the
synergy we observed between GNF179 and brefeldin A, GNF179
could inhibit COPI-mediated transport from the ER to the Golgi,
similar to the mechanism of action of brefeldin A73. Sar1, an
essential gene involved in the Sec23 complex, for example, is a
small GTPase that functions as a target in a yeast brefeldin
suppressor screen73. The lysine transferase that adds acetyl
groups to nascent peptides, helping them fold and which relies on
PfACT activity could be a target.
Protein glycosylation in the ER may could also be inhibited
and may lead to unfolded aggregates within the ER. Tunicamycin,
a nucleoside analog, inhibits protein N-linked glycosylation by
preventing core oligosaccharide addition to nascent polypeptides
by binding to UDP-N-acetylglucosamine--dolichyl-phosphate N-
acetylglucosamine phosphotransferase (Alg7). Tunicamycin thereby
also blocks protein folding and transit through the ER. The P. fal-
ciparum version of Alg7, PF3D7_0321200, could theoretically be
a target, although the structure of KAF156 is not similar to
tunicamycin.
It is also worthwhile to note that several additional compounds
may work via similar or related mechanisms. For example,
mutations in pfcarl are acquired when parasites are treated with
sublethal concentrations of MMV00756425. In particular, if there
is a pfcarl or pfact resistance mechanism, it seems likely that
protein folding or trafficking in the ER is targeted. More work will
be needed to determine whether MMV007564 has the same target
as KAF156 or if they only act against the same pathway. By
comparison, there are a variety of different chemotypes that
inhibit mitochondrial function74, as well as different chemotypes
that interact with the same active site, however, there still seem to
be a limited number of high-value inhibitor binding sites in this
pathway, and they appear repeatedly.
An additional mechanism of action for IZPs could be inhi-
biting the process of ER autophagy. The mammalian orthologue
of Sec62, potentially a target of GNF179, is required for the
degradation of excess ER components in a process termed ER
autophagy75. In vitro directed evolution of S. cerevisiae using
GNF179 identified mutations in the atg15 and atg22, genes that
play a role in ER-autophagy. In addition, GNF179 induced an
expansion in ER size upon treatment of P. falciparum. Collec-
tively, these results suggest that IZPs affect ER homeostasis and
function by inhibiting proteins critical for ER-phagy.
Strategies for finding the target of KAF156 remain limited in
the absence of genetic methods, and few antimalarials have been
matched with their target when genetic methods fail. Affinity-
based methods were used to match MMV030048 to PI4K with
success76, although such strategies required the use of a modified
ligand. Cellular Thermal Shift Assays (CETSA) methods that
involve incubating total cellular extracts with an unmodified
ligand and identifying those proteins that resist heat denaturation
in the presence of compound is a strategy that shows promise77.
Another potential option involves a genome-wide knockdown or
knock-in libraries, which have been used with success in trypa-
nosomes and to find the target of cladosporin also using the S.
cerevisiae model78. A limitation of all of these genome-wide
methods is that they may produce hundreds of possible candidate
molecules, and it can be challenging to sort through them using
the slow methods available in Plasmodium. While finding the
exact target may require further work, the studies here should
allow prioritization of candidates that are identified in genome-
wide experiments.
Methods
Resistance evolution of GNF179-resistant S. cerevisiae. Sublethal concentra-
tions of GNF179 were added to 50 ml conical tubes containing 20 µl of saturated S.
cerevisiae ABC16-Monster cells in 20 ml of YPD media. Each selection was cultured
under vigorous shaking until the culture reached saturation. Saturated cultures
were diluted into fresh YPD media containing increasing GNF179 concentrations,
and multiple rounds of selection were performed. Cells of cultures that were able to
grow in substantially higher drug concentrations than the parental cell line, were
streaked onto agar plates containing GNF179 to select for single colonies. Single
colonies were isolated, and IC50 assays, prepared by two-fold dilution were per-
formed to determine the degree of evolved resistance vs. that of the parental strain.
Whole-genome sequencing of GNF179-resistant S. cerevisiae. Genomic DNA
(gDNA) was extracted from yeast samples using the YeaStar Genomic DNA kit
(Cat. No D2002, ZYMO Research). Sequencing libraries were prepared using the
Illumina Nextera XT kit (Cat. No FC-131-1024, Illumina) following the standard
dual indexing protocol, and were then sequenced on the Illumina HiSeq 2500 in
RapidRun mode to generate paired-end reads 100 bp in length. Reads were aligned
to the S. cerevisiae 288 C reference genome (assembly R64) using BWA-mem79 and
further processed using Picard Tools (http://broadinstitute.github.io/picard/). A
total of 13 clones were sequenced to an average coverage of 47.3×, with an average
of 99.3% of reads mapping to the reference genome. SNVs and INDELs were called
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using GATK HaplotypeCaller, filtered based on GATK recommendations80 and
annotated with SnpEff81. Variants were further filtered by removing mutations that
were present in the both drug-sensitive parent strain and resistant strains, such that
mutations were only retained if they arose during the drug selection process.
Evolved yeast strains used in this study are listed in Supplementary Table 2.
CRISPR-Cas9 allelic exchange in S. cerevisiae. CRISPR-Cas9 genome engi-
neering was performed on the S. cerevisiae ABC16-Monster strain using vectors
p414 and p426 obtained from the Church lab (Addgene) as previously descri-
bed29. To produce gRNA plasmids specific to the desired mutation sites, oligo-
nucleotides were synthesized (Integrated DNA Technologies) to match the target
sequence and contain a 24 base-pair overlap with the p426 vector backbone.
Gene-specific gRNAs were amplified by PCR, transformed into StellarTM com-
petent E. coli cells (Takara) and selected on LB-Ampicillin plates. DNA was
isolated from transformed E. coli cells and purified using the QiaQuick Miniprep
kit (Qiagen) and quantified via Qubit Fluorometric Quantitation (ThermoFisher).
Cas9-expressing ABC16-Monster cells were transformed with 300–500 ng of
gene-specific gRNA vector and 1–2 nmole of synthesized donor template (IDT)
containing the desired base-pair substitution via standard lithium acetate
method. Transformed cells were selected on methionine and leucine deficient
CM-glucose plates. Each mutation was confirmed with Sanger sequencing (Eton
Bioscience). Sequences of primers and oligonucleotides used for this study can be
found in Supplementary Table 3. Edited yeast strains generated for this study are
listed in Supplementary Table 2.
P. falciparum culture. P. falciparum Dd2 strain parasites were cultured under
standard conditions82, using RPMI media (Thermo Fisher # 21870076) supple-
mented with 0.05 mg/ml gentamycin (Thermo Fisher # 15710072), freshly-
prepared 0.014 mg/ml hypoxanthine (Sigma Aldrich #H9377), 38.4 mM HEPES
(Sigma Aldrich #H3375), 0.2% Sodium Bicarbonate (Sigma Aldrich #S5761),
3.4 mM Sodium Hydroxide (Sigma Aldrich #S8045), 0.05% O+ Human Serum
(Denatured at 560C for 40 min and obtained from Interstate Blood Bank, Mem-
phis, TN) and 0.0025% Albumax (Thermo Fisher Scientific # 11021037). Human
O+ whole blood was obtained from The Scripps Research Institute (La Jolla, CA)
using the Normal Blood Program and Humann Subjects Protocol Number (IRB-
12-5933). Leukocyte-free erythrocytes were stored at 50% hematocrit in RPMI-
1640 screening media (as above, but without O+ human serum and with 2x
albumax concentration) at 4 °C for one to three weeks before experimental use.
Cultures were monitored every one to two days via direct observation of parasite
infection using light microscopy-based observation of Giemsa-stained thin blood
smears of parasite cultures. Specific parasite cultures used are as indicated in the
specific experiments. Additionally, all parasite strains used for this study are listed
in Supplementary Table 2.
Sphingolipid quantitation. Parasites were grown in culture media containing both
human serum (5%) and albumax (0.25%) at 3% hematocrit. Asynchronous para-
sites (containing ~2/3 rings) were treated with GNF179 for 4 h at 5X wild type IC50
(25 nM). Parasitized cells were then washed with PBS (+drug for GNF179-treated
samples). Samples were then lysed with 5 volumes of 0.15% saponin (in cold PBS)
on ice for 20 min, and centrifuged and washed extensively. Parasite pellets were
flash frozen in liquid nitrogen and stored at −80 °C until use.
Protein concentrations were measured using the Bradford Protein Assay for
biological (n= 3) and technical (n= 2) replicates for WT and mutant parasites ±
drug. Samples were solubilized using cell lysis buffer comprising 1 M Tris, 20%
SDS, 0.5 M EDTA, β-mercaptoethanol and double distilled water then boiled at
95 °C for 5 min. Bovine serum albumin (BSA) standards and parasite samples were
incubated with Bradford Reagent (BioRad) at room temperature for 15–30 min
then absorbance read at 595 nm in order to derive protein concentrations.
For lipid extraction, parasite samples and controls for lipid analysis were
prepared in a 96-well plate comprising a final volume of 50 μl per well. To each
well, 50 μl internal standards comprising ceramide (C12) and sphingomyelin
(SM12) were added. Lipids were extracted from parasite and control samples using
900 μl dichloromethane/methanol (1:1 v/v). The plate was vortexed overnight at
room temperature then centrifuged to pellet out all insoluble material. The
supernatant containing lipids was transferred into a new plate and samples
subjected to mass spectrometry using a triple quadrupole LC-MS system. Briefly,
7 μl of sample was injected into the HPLC running through a C18 Poroshell
column into Agilent QQQ 6430 MS/MS. HPLC was optimized under the following
conditions: mobile phase A (water/methanol/ chloroform/0.1% formic acid) and
mobile phase B (methanol/ acetonitrile/chloroform/0.1% formic acid). Analysis
was done on Agilent Quantitative Analysis software and normalized to total
protein in the samples. All sample data sets were analyzed using Graph Pad Prism
4.0 and sphingolipid content was compared across all possible combinations of
data in treated (+) and untreated (−) wild type (Dd2) and pfcarl mutant
(KAD452-R3) parasites.
Evaluating protein trafficking defects. P. falciparum parasites expressing
PfEMP3-GFP or PfSERA5ss-GFP were generated as previously described in ref. 49,
with the indicated reporters cloned into pGLUX.1 and their expression driven by
the PfCRT promoter. P. falciparum trophozoites expressing PfEMP3-GFP or
PfSERA5ss-GFP were magnetically-purified (Miltenyi Biotech), incubated with
1 µM and 10 µM GNF179, 10 μM brefeldin A, 100 μM cycloheximide, and 10 μM
ZLL2 for 4 h at 37 °C, and treated with 0.09% saponin-containing inhibitor.
Washed pellets were solubilized in 2x Laemmli buffer (Bio-Rad #1610737) then
boiled for 3 min. Proteins were then separated by SDS-PAGE, transferred to
nitrocellulose and blocked in 1% skim milk. Membranes were probed with mouse
anti-GFP (Roche, cat. no. 11814460001) (1:1000) (primary validation is provided
on the manufacturer’s website) or rabbit anti-HSP70 (1:4000), subsequently fol-
lowed by probing with species-matched horseradish peroxidase HRP–conjugated
secondary antibodies (Cell Signaling Technology, cat. nos. 7074 and 7077) and
visualization with enhanced chemiluminescence (Amersham). Supplementary
Fig. 7 shows uncropped GFP- and HSP70-probed blots corresponding to three
independent experiments.
For endogenous proteins, 3D7 wild-type Plasmodium parasites were treated
with the indicated concentrations of GNF179 for 3 h at 37 °C, and treated with
0.09% saponin-containing inhibitor. Immunoblotting was performed as described
above using antibodies for PfIESP2, PfSERA5 and PfPTP283.
Evaluating Ubiquitination and eIF2α phosphorylation. To measure ubiquitin
response after GNF179 treatment, P. falciparum trophozoites expressing PfEMP3-
GFP or PfSERA5ss-GFP were magnetically-purified (Miltenyi Biotech), incubated
with 10 µM MG132 alone, 10 µM GNF179 alone, and a combination of 10 µM
MG132 and 10 µM GNF179 for 3 hours at 37 °C. The parasitized RBCs were then
treated with 0.09% saponin-containing inhibitor. Washed pellets were solubilized
in 2x Laemmli buffer (Bio-Rad #1610737) then boiled for 3 min. Proteins were then
separated by SDS-PAGE, transferred to nitrocellulose and blocked in 1% skim
milk. Membranes were probed with mouse anti-Ubiquitin (PD41 Cell Signalling
Technology #3936) (1:1000) or rabbit anti-HSP70 (1:4000), subsequently followed
by probing with species-matched HRP–conjugated secondary antibodies (Cell
Signaling Technology, cat. nos. 7074 and 7076) and visualization with enhanced
chemiluminescence (Amersham).
To measure eIF2α phosphorylation after GNF179 treatment, highly
synchronized, wild-type (Dd2-strain) P. falciparum early trophozoites were
incubated for 90 minutes at 37 °C with 0.5 µM/5 µM Chloroquine, 0.5 µM/5 µM
GNF179, 0.1 mM/1 mM brefeldin A, and 5 mM DTT. The parasitized RBCs were
then lysed using 0.09% Saponin, and pellets were solubilized in 2x Laemmli buffer
(Bio-Rad #1610737) then boiled for 3 min. Proteins were then separated by SDS-
PAGE, transferred to nitrocellulose and blocked in 5% bovine serum albumin
(BSA). Membranes were subsequently probed with rabbit anti-eIF2α-p (Cell
Signaling Technology-119A11) (1:800) or mouse anti-HSP70 (1:2500), followed by
incubation with species-matched, HRP-conjugated secondary antibodies, and then
visualized using chemiluminescence (ThermoFisher Scientific).
Sec62 knockdown assay. 3D7 wild type and PfSec62-HA-glmS transgenic para-
sites55 were synchronized using sorbitol at ring stage and incubated with 0 mM and
1 mM Glucosamine (Sigma). GNF179, chloroquine and mefloquine were added at
increasing concentrations and all cultures incubated for 48 hrs until the late ring
stage of the successive cycle. Parasitaemia at each drug concentration was assessed
by flow cytometry and all data tabulated using GraphPad Prism.
Measuring parasite translation using 35S-incorporation. The effect of drug
treatment on parasite translation was evaluated by quantifying the incorporation of
35S-labeled amino acids into newly synthesized protein by adapting a published
protocol84. Briefly, synchronized, trophozoite-stage parasites (5% parasitemia, 26-
30 hpi) were first washed in methionine-free media three times prior to drug
treatment. Parasites were then incubated in various compound concentrations in
24-well plates for 1 h at 37 °C, at a final hematocrit of 5%, and a final concentration
of 125 µMci/mL of EasyTag™ EXPRESS 35S Protein Labeling Mix (Perkin Elmer,
USA). Concentrations used for incubation correspond to 100-, 10-, 1-, 0.1-, and
0.01-times the IC50 values of KAF156 (15 nM), chloroquine (85 nM) and cyclo-
heximide (750 nM). After incubation, parasites were washed with 1x PBS and then
lysed using ice-cold 0.15% saponin in 1x PBS for 20 min. All subsequent steps were
performed on ice. The saponin pellet was washed with 1x PBS, and then resus-
pended in 0.02% sodium deoxycholate and supplemented with an equal volume of
16% trichloroacetic acid (TCA) to make a final concentration of 8% TCA. The
suspensions were then incubated for 20 min on ice before vacuum filtration. To
collect the radiolabeled, precipitated proteins, the samples were dispensed onto
0.7 µM glass fiber filter discs (Millipore, USA) that had been presoaked in 8% TCA.
The vacuum-filtered precipitates were then washed twice with 8% TCA and then,
finally, with 90% acetone. The filter discs were allowed to air-dry for at least two
hours, transferred into scintillation vials and resuspended in scintillation cocktail
(Perkin Elmer, USA). 35S counts were obtained for 1 min using a Beckman Coulter
LS 6500 Multi-purpose Scintillation Counter. Counts were normalized to data
obtained from untreated parasites.
Assessment of new permeation pathways. Parasites were cultured as above.
Three parasite strains were used, wild-type Dd2, KAD452-R3, and Dd2 ACT S242*
(Dd2 act - PF3D7_1036800 – with S242* SNV24). Each parasite clone was split into
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three sets of matched cultures. Each set of matched cultures was either treated for
4 h at 37 °C with compound (50 nM GNF179, 500 nM Chloroquine or 5 µM bre-
feldin A (Sigma Aldrich #B6542)) or an equal volume of DMSO. After drug
treatment, cultures were synchronized by treatment with 5% sorbitol (Sigma
Aldrich # 240850) for 10 min at 37 °C, washed once with media and returned to
normal culture conditions. 24 h after treatment, cultures were assessed by thin
blood smear and GIEMSA staining for parasite lifecycle stage. The proportion of
early (“ring”) stage parasites to the total parasite proportion was recorded.
Microscopy methods parasite culture. P. falciparum asexual blood stage parasites
were cultured in human erythrocytes (3% hematocrit) and RPMI-1640 media
supplemented with 2 mM L-glutamine, 50 mg/L hypoxanthine, 25 mM HEPES,
0.225% NaHCO3, 10 mg/L gentamycin, and 0.5% (w/v) Albumax II (Invitrogen).
Parasites were maintained at 37 °C in 5% O2, 5% CO2, and 90% N2. Cultures were
stained with Giemsa, monitored by blood smears fixed in methanol, and viewed by
light microscopy.
Export block assay. The KAHRP69-GFP reporter line was generated by ampli-
fying the first 207 bp of the KAHRP gene (PF3D7_0202000), which includes the
signal peptide and PEXEL motif, followed by a glycine linker, and cloning
upstream of GFP in the pDC2-crt-attP-BSD vector under the control of the pfcrt 5’
UTR. The plasmid was integrated by attB x attP recombinase-mediated integration
into the Dd2attB parasite line85. Dd2attB KAHRP69-GFP ring stage parasites were
incubated with either 5×IC50 GNF179 (25 nM), brefeldin A (5 µg/ml) (Sigma
Aldrich) or DMSO-mock treated 16 h prior to imaging. For live-cell imaging, 5 µl
of resuspended culture was added to 30 µl of RPMI-1640 media (without Albumax
II) containing Hoechst 33342 (1 µg/ml) (Sigma) and imaged at room temperature
after 5 min incubation at 37 °C. For experiments with ER-TrackerTM Red (Thermo
Fisher), the dye was added to a final concentration of 1 µM 30 min prior to ima-
ging. Indirect Immunofluorescence assays (IFAs) were performed in suspension.
Cells were fixed in 4% (v/v) formaldehyde (Thermo Fisher Scientific) for 1 h at RT
followed by a second fixation step supplementing the 4% formaldehyde solution
with 1 mM Cysteine and CaCl2 and subsequent incubation over night at 4 °C. The
cells were permeabilized on ice using 0.05% Triton X-100 in 1x PBS for 5 min and
autofluorescence was quenched using 50 mM glycine for 10 min. After two washes
in 1x PBS the cells were resuspended in 1% (w/v) bovine serum albumin (BSA) in
1x PBS blocking buffer and incubated with the appropriate dilution for each pri-
mary antibody used (1/200 for anti-ERD2, 1/200 for anti-PDI (Mouse anti-PDI
(1D3), Enzo Life Sciences, Cat. No. ADI-SPA-891-D), 1/500 for anti-GFP) followed
by an incubation with the species-specific corresponding secondary antibody
(Alexa Fluor 488-, 594- or 647- conjugated goat anti mouse or rabbit antibodies,
Thermo Fisher) diluted 1:2000 in 1% BSA in 1x PBS.
Parasites were imaged using a Nikon Eclipse Ti-E wide-field microscope
equipped with a sCMOS camera (Andor) and a Plan-apochromate oil immersion
objective with 100× magnification (1.4 numerical aperture). A minimum of 27 Z-
stacks (0.2 μm step size) were taken of each parasitized RBC. NIS-Elements
imaging software (Version 5.02, Nikon) was used to control the microscope and
camera as well as to deconvolve the images (using 25 iterations of the Richardson-
Lucy algorithm for each image) and perform 3D reconstructions. Quantitative co-
localization analysis of the deconvolved Z-stacks was performed using the GA3
pipeline (General analysis Pipeline 3; NIS-Elements software; developed in
collaboration with Nikon). ImageJ (Fiji) (version 2.0.0-rc-68/1.52 h) was used to
crop the images, adjust brightness and intensity, overlay channels and prepare
montages.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All genome sequences for the 13 IZP-resistant S. cerevisiae strains have been placed in the
short-read sequence archive [http://www.ncbi.nlm.nih.gov/sra] under accession code
STUDY: PRJNA381796 (SRP107357). The source data underlying Figs. 2b, 3c, 4e, 4f, and
4h are provided as Source Data file.
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